Kalbus O. I.

INDICATORS OF OXIDATIVE AND NITROSIN STRESS IN GENERALIZED MYSTENA


About the author:

Kalbus O. I.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scentific article

Annotation:

Although the relationship between oxidative stress (OS) as well as nitrosine stress (NS) and myasthenia gravis has been poorly studied, some studies indicate a role for OS in the pathogenesis of myasthenia gravis development. The purpose of this work was to study the role of the OS and NS in the development of generalized myasthenia gravis. Object and methods. A total of 147 patients with generalized myasthenia gravis and 10 near-healthy controls were included into the study. The MGFA classification (Myasthenia Gravis Foundation of America, 2001) was used to evaluate the clinical form, class and subclass of myasthenia gravis. The level of total protein, sulfhydryl groups (SH-groups), level of glutathione-dependent enzymes (glutathione peroxidase – GPO, glutathione reductase – GR, glutathione-S-transferase – GT) were evaluated. In addition, the level of reduced (GSH) and oxidized (GSSG) glutathione, heat shock protein 70 kDa mass (HSP70) was determined. The level of nitrotyrosine was determined as the main indicator of the NS. Methods of parametric and non-parametric statistics were used in mathematical data processing. Results and Discussion. Of the total sample of patients with generalized form, 52 (28.6%) had MGFA class II myasthenia, 64 (35.2%) had class III, 31 (17%) had class IV myasthenia accordingly. The level of total blood protein ranged from 62.9 g/l to 95.0 g/l in all surveyed patients. The average level (M(SD)) in the control group was 77.5 (4.59) and among patients with generalized myasthenia gravis – 75.9 (7.23) g/l, with no statistically significant differences between generalized form and control, as well as between classes and subclasses of the disease (p> 0.05). Within the ANOVA, the degree of influence of an independent factor (disease class) on the investigated trait – the investigated protein, the enzyme of the antioxidant system (K,%) – was evaluated.Significant influence of the myasthenia class on the variability of oxidative stress and heat shock proteins was found: the greatest influence was on the SH-group fluctuations (K = 75.45%; p <0.001), then (in descending order) – on oxidized and reducing glutathione (respectively K = 73.24% and K = 72.29%; p <0.001), HSP (K = 62.08%; p <0.001), GPO (K = 60.34%; p <0.001), GR (K = 56 , 66%; p <0.001), nitrotyrosamine (K = 48.58%; p <0.001) and the lowest one – GT-glutathione-S-transferase (K = 32.0%; p = 0.001). Therefore, by the analysis of indicators of oxidative and nitrosative stress and heat shock proteins, we can conclude that with generalized myasthenia, with increasing its severity develops a state of chronic oxidative stress, which is an indicator of the decrease of the activity of antioxidant enzymes and increase of enzymes – promoters of metabolic processes. These dependencies are confirmed by correlation analysis. By rank correlation analysis it was determined that glutathione peroxidase correlates with MGFA disease class and subclass (Spearman rank correlation coefficients, respectively, ρ = -0.44 and ρ = -0.44; p <0.001); glutathione reductase (respectively, ρ = -0.60 and ρ = -0.61; p <0.001); GT-glutathione-S-transferase (respectively ρ = -0.53 and ρ = -0.54; p <0.001) and heat shock protein HSP70 (respectively ρ = -0.74 and ρ = -0.71; p < 0,001). Conclusions. With increasing clinical manifestations of generalized myasthenia, there is a decrease in the concentration of antioxidant enzymes and an increase in the concentration of promoter enzymes of metabolic processes, which is a sign of the development of chronic oxidative stress

Tags:

myasthenia gravis, oxidative stress, nitrosine stress, glutathione, heat shock protein, nitrotyrosamine

Bibliography:

  1. Kalbus OI. Kliniko-imunologichni spivstavlennya u khvorykh na miasteniyu. Ukr. journal medicinу, biol. ta sport. 2018;3(1):135-8. Dostupno: https://doi.org/10.26693/jmbs03.01.135 [in Ukrainian].
  2. Sanadze AG. Miasteniya i miastenicheskie sindromy: rukovodstvo. M.: GEOTAR-Media; 2017. 256 s. [in Russian].
  3. Engel A. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 2012. 304 p.
  4. Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta neurologica Scandinavica. Supplementum. 2014;198:26-31. Available from: https://doi.org/10.1111/ane.12233
  5. Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. Journal of Clinical Neuroscience. 2015;22(7):1164-9. Available from: https://doi.org/10.1016/j.jocn.2015.01.022
  6. Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders. 2016;26(1):41-6. Available from: https://doi.org/10.1016/j.nmd.2015.10.009
  7. Breiner A, Young J, Green D, Katzberg H, Barnett C, Bril V, et al. Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. Neuroepidemiology. 2015;44(2):108-13. Available from: https://doi.org/10.1159/000375463
  8. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurology. 2010;10:46. Available from: https://doi.org/10.1186/1471-2377-10-46
  9. Kalbus OI. Medyko-statystychni ta epidemiolohichni kharakterystyky poshyrenosti miasteniyi v Ukrayini. Ukr medical journal. 2019;2(2):42-5. Dostupno: https://doi.org/10.32471/umj.1680-3051.132.161828 [in Ukraininan].
  10.  Brambilla D, Mancuso C, Scuderi M, Bosco P, Cantarella G, Lempereur L, et al. The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. Nutrition Journal. 2008;7(1):29. Available from: https://doi.org/10.1186/1475-2891-7-29
  11. Yang D, Su Z, Wu S, Bi Y, Li X, Li J, et al. Low antioxidant status of serum bilirubin, uric acid, albumin and creatinine in patients with myasthenia gravis. International Journal of Neuroscience. 2016;126(12):1120-6. Available from: https://doi.org/10.3109/00207454.2015.1134526
  12. Krishnaswamy A, Cooper E. Reactive oxygen species inactivate neuronal nicotinic acetylcholine receptors through a highly conserved cysteine near the intracellular mouth of the channel: implications for diseases that involve oxidative stress. The Journal of Physiology. 2011;590(1):39- 47. Available from: https://doi.org/10.1113/jphysiol.2011.214007
  13. Venkatesham A, Babu PS, Sagar JV, Krishna DR. Effect of reactive oxygen species on cholinergic receptor function. Indian J Pharmacol. 2005;37:366-70.
  14. Adamczyk-Sowa M, Bieszczad-Bedrejczuk E, Galiniak S, Rozmiłowska I, Czyżewski D, Bartosz G, et al. Oxidative modifications of blood serum proteins in myasthenia gravis. Journal of Neuroimmunology. 2017;305:145-53. Available from: https://doi.org/10.1016/j.jneuroim.2017.01.019

Publication of the article:

«Bulletin of problems biology and medicine» Issue 3 (152), 2019 year, 121-127 pages, index UDK 616.74+616.8]-009.17:612.176]-092

DOI: